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Abstract There is substantial genetic and epidemiologi-
cal evidence implicating vitamin D in the pathogenesis of
many common diseases. A number of studies have sought
to define an association for disease with sequence variation
in the VDR gene, encoding the ligand-activated nuclear
hormone receptor for vitamin D. The results of such studies
have been difficult to replicate and are likely to need to
account for specific environmental exposures. Here, we
review recent work that has begun to study the interactions
between VDR gene polymorphisms, vitamin D blood lev-
els, and complex disease susceptibility, notably in the
context of major clinical outcomes. We highlight the
challenges moving forward in this area and its importance
for effective clinical translation of current research.
1 Introduction
Vitamin D deficiency has been associated with a number of
diseases but causality and molecular mechanisms remain
poorly understood. Vitamin D is a secosteroid hormone
classically known for its function in calcium metabolism
and bone physiology with the first descriptions of rickets
made in the 1600s by Whistler and Glisson [1]. The
broader role of vitamin D in health and disease is
highlighted by studies demonstrating its importance in
inflammatory conditions and the adaptive and innate
immune response. Epidemiological data, animal models,
and genetic studies provide evidence of a role for vitamin
D in diseases from cardiovascular disease (CVD) to type 1
diabetes mellitus and multiple sclerosis (MS) [2–5]. A
recent study indicates that VDR polymorphisms may
interact with circulating levels of vitamin D (25(OH)D) in
determining major clinical outcomes, including a com-
posite outcome of incident hip fracture, myocardial
infarction (MI), cancer, and mortality [6]. Here, we focus
on this recent evidence, review meta-analysis studies of
VDR polymorphisms and disease, and highlight aspects
relevant for future research.
1.1 Sources and Metabolism of Vitamin D
Humans obtain vitamin D from skin exposure to ultraviolet B
radiation (UVR) or through dietary intake. The metabolism
is complex with many intermediate steps. UVR converts
7-dehydrocholesterol to pre-vitamin D3, which is immedi-
ately transformed through a heat-dependent process to
vitamin D3 [7, 8]. Vitamin D3 (from UVR exposure) or D2
(dietary) is transported by chylomicrons and stored in adi-
pocytes or transported to other tissues by the vitamin
D-binding protein (GC) [8, 9]. Vitamin D-25-hydroxylase
(CYP2R1) metabolizes vitamin D to 25-hydroxyvitamin D
(25(OH)D), the form most commonly measured and used to
determine vitamin D status in an individual [10, 11]. The
active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25(OH)2D), is obtained by conversion of 25(OH)D
by 25-hydroxyvitamin D-1a-hydroxylase (1-OHase;
CYP27B1). CYP2R1 and CYP27B1 are expressed at high
levels in the liver and kidney, respectively, although they are
found in multiple tissues [10]. 1,25(OH)2D is catabolized by
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1,25-dihydroxyvitamin D 24-hydroxylase (CYP24A1) to
form calcitroic acid and is excreted in bile [10].
The actions of vitamin D are largely mediated through
the vitamin D receptor (VDR). VDR is ligand activated by
1,25(OH)2D and as a heterodimer with the retinoid-X
receptor (RXR) travels to the nucleus to bind vitamin D
response elements. DNA-bound 1,25(OH)2D-VDR-RXR
complexes regulate genome-wide transcriptional expres-
sion through incompletely understood mechanisms [12].
Although the most important source for vitamin D is
exposure to sunlight, dietary supplementation is important
for individuals at risk of deficiency. This is increasingly
true for populations away from the equator, individuals
with dark skin, those who use excessive sunscreen, and
those who do not expose their skin to sunlight for religious
or lifestyle reasons. As such, adequate guidelines for sun
exposure and vitamin D supplementation remain necessary,
particularly for at-risk groups.
1.2 Genetic Determinants of Plasma Vitamin D Levels
The circulating form of vitamin D, 25(OH)D, is the most
commonly measured and used form to describe an indi-
vidual’s vitamin D status [9]. The definition of normal
levels is contentious, particularly for non-skeletal func-
tions. A recent report from the Institute of Medicine in the
USA highlighted the need for rigorous evidence to be
collected for non-classic effects of vitamin D and recom-
mended plasma levels to be 50–150 nmol/L [13].
Recent studies have indicated that heritability of
25(OH)D in plasma can be high. It is estimated that
*25 % of inter-individual variability can be attributed to
season of measurement, latitude, or intake [14]. A study in
male monozygotic twins showed significant seasonal var-
iation with a 15 nmol/L lower value during the winter than
during the summer. It was estimated that 70 % of the
variation during winter was explained by genetic factors,
though in the summer, levels did not have a discernible
heritable component [15]. Karohl and colleagues (2010)
also confirmed a previous finding of significantly higher
intra-class correlation between monozygotic twins com-
pared with dizygotic twins [16].
Two recent genome-wide association studies (GWAS)
found that common variants present in CYP2R1, 7-DHCR,
CYP24A1, and in the vitamin D binding protein (GC,
DBP), were associated with 25(OH)D blood levels [14].
These genetic markers and genotype combinations were
associated with an increased risk of vitamin D insufficiency
(\75 nmol/L), deficiency (\50 nmol/L), and severe defi-
ciency (\20 nmol/L) [14, 17]. Interestingly, rs2282679
within the GC gene was also significantly associated with
concentrations of GC protein with the minor allele asso-
ciated with lower levels (Table 1) [14].
1.3 The Vitamin D Receptor
The discovery of VDR in the jawless primitive fish (lam-
prey) led to the conclusion that the vitamin D system
originated before the development of calcified structures
[18]. Ultraviolet irradiation in invertebrates, fungi, and
plants generates vitamin D2 and thus vitamin D may have
developed as a system to help prevent damage to nucleic
acids and proteins [19]. VDR’s structural similarity to other
nuclear receptors involved in bile acid and xenobiotic
receptors raises the possibility that its initial importance
related to detoxification and later evolved to calcium
homeostasis and immunity [1]. The VDR gene is conserved
across species including non-human primates, rodents,
birds, and flies and it seems likely that it has been posi-
tively selected in humans [20]. It is thought that skin color
evolved to address vitamin D synthesis [21]. Vitamin D
deficiency leading to disorders such as rickets-induced
pelvic fractures can have fatal consequences and may have
driven selection to some extent [22].
VDR is found in the nucleus as a homodimer in the
absence of 1,25(OH)2D3. The VDR protein can bind to the
three isoforms of RXR and acquires the active conforma-
tion when bound to 1,25(OH)2D3. More than 900 allelic
variants have been described at the VDR locus (1000
Genomes Browser v. 3; Homo sapiens: GRCh37.p11, Chr
12 (NC_000012.11): 48.23–48.29 M). A small number of
these have been studied with several disease associations
reported. Importantly, loss-of-function mutations in the
VDR gene cause hereditary vitamin D-resistant rickets type
II [23, 24]. ApaI [rs7975232], BsmI [rs1544410], FokI
[rs10735810], and TaqI [rs731236]) are single nucleotide
polymorphisms (SNPs) in VDR that have been widely
studied in relation to common disease, initially using
restriction enzyme assays from which the nomenclature
derives from (Fig. 1) [25–27]. Alleles identified by
restriction sites are noted in upper (absence) and lower
(presence) case respectively (e.g., ‘F’ or ‘f’ for FokI).
1.4 Vitamin D Blood Levels, VDR Polymorphisms,
and Major Clinical Outcomes
It is possible that genotypic effects are only evident under
particular environmental contexts. A recent study showed
that the combination of low circulating 25(OH)D levels
and genotype increases disease risk for multiple outcomes
[6]. Levin et al. [6] undertook a candidate gene approach to
test whether common polymorphisms in vitamin D
metabolism genes (VDR, CYP27B1, CYP24A1, GC, LRP2,
and CUBN) interacted with circulating 25(OH)D and were
associated with disease [6]. A composite outcome of
incident hip fracture, MI, cancer, and mortality after a
follow-up of 11 years in the discovery cohort was used.
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Independent replication was done using three additional
cohorts from different populations with follow-ups of at
least 7 years. The discovery cohort identified interactions
between five SNPs and low circulating 25(OH)D levels.
One SNP implicating VDR was replicated independently
and low circulating 25(OH)D levels were associated with
increased risk of the composite outcome with allelic dos-
age. Individuals with low circulating 25(OH)D levels and
one minor allele at rs7968585 had a hazard ratio (HR) of
1.40 (95 % confidence interval [CI] 1.12–1.74) for the
composite outcome while individuals with two alleles had
a HR of 1.82 (95 % CI 1.31–2.54). Homozygous individ-
uals for the major allele at rs7968585 showed no
association.
This study is of special interest given the number of
reported associations of vitamin D deficiency with disease.
The magnitude and direction of the risks conferred by
genetic variants were relatively consistent across popula-
tions and individual disease outcomes. However, hetero-
geneity was significant in the meta-analysis for two
variants, and borderline non-significant for a third. Using a
composite outcome may add statistical power but the bio-
logical reasoning is not immediately evident. Although
vitamin D has many actions it would seem unlikely that it
has a causal effect in multiple diseases with diverse path-
ophysiological mechanisms. The study by Levin et al. [6]
is, to our knowledge, one of the first to use an analysis
based on composite outcomes for VDR polymorphisms,
disease association, and environmental interaction. Further
studies assessing larger independent cohorts and interro-
gating homogenous outcomes will be required to confirm
and refine these findings. Here, we set the results in a
broader context by first highlighting recent systematic
reviews and meta-analyses for each condition to contex-
tualize these findings.
1.5 Genetic Evidence of Association Involving
the Vitamin D Receptor
1.5.1 Hip Fracture
Candidate gene studies testing the association of VDR
polymorphisms and fracture have had mixed results. A
meta-analysis suggested that there is a statistically signifi-
cant association between BsmI and fracture risk [28]. By
contrast TaqI, associated in the Levin et al. study, and other
variants were not significant.
1.5.2 Type 2 Diabetes Mellitus
Studies showing an association between VDR polymor-
phisms and susceptibility to type 2 diabetes have been
inconsistent. A recent meta-analysis to analyse the asso-
ciation of four well-studied VDR polymorphisms (FokI,
Table 1 Single nucleotide polymorphisms associated with vitamin D plasma levels by genome-wide association studies
References Reported gene(s) Strongest SNP Risk allele frequency P value OR (P value)*
Ahn et al. [17] GC rs2282679 0.26 1.8E-49 1.83 (2.50E-8)
CYP2R1 rs2060793 0.41 2.9E-17 0.89 (0.21)
NADSYN1, DHCR7 rs3829251 0.19 3.4E-09 1.18 (0.11)
Wang et al. [14] GC rs2282679 0.29 1.9E-109 1.63 (3.5E-50)
CYP2R1 rs10741657 0.40 3.3E-20 1.21 (4.1E-10)
NADSYN1, DHCR7 rs12785878 0.23 2.1E-27 1.21 (9.4E-11)
SNP single nucleotide polymorphism, OR odds ratio
* Association of one risk allele with \25 nmol/L (Ahn et al.) and \75 nmol/L (Wang et al.)
Fig. 1 The human vitamin D receptor gene showing polymorphisms
associated with disease. VDR spans 105 kb at chromosome 12q13.11.
Studies independently investigating hip fracture, type 2 diabetes,
rheumatoid arthritis (RA), MI, cancer, and other diseases such as MS,
tuberculosis and type 1 diabetes have reported associations with VDR
gene polymorphisms. dbSNP (rs) identifiers and nomenclature
derived from restriction enzyme cleavage sites are shown in the
context of the region chr12:46,524,238–46,525,237 on the negative
strand (UCSC release hg18, March 2006). Exons marked 1f–1c are
largely non-coding and are indicated by open bars. Black bars
indicate coding exons 2–9 with transcriptional start sites marked by
arrows. Figure reproduced with permission from [26]
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BsmI, ApaI, and TaqI) with type 2 diabetes susceptibility
found that the FokI polymorphism, but not TaqI or others,
was significantly associated with an increased risk of type 2
diabetes in an Asian population [29]. None of the poly-
morphisms studied had significant associations in other
populations.
A recent trial investigated the effect of VDR FokI
polymorphism and vitamin D intake on glycemic status,
lipid profiles, and inflammatory biomarkers in 140 diabetic
subjects. It found that FokI (FF vs. ff) is associated with
increased levels of plasma 25(OH)D and decreased levels
of C-reactive protein (CRP) and interleukin (IL)-6 fol-
lowing 12 weeks of 1,000 IU per day [30]. The study
concluded that individuals with the FF genotype, when
compared with those with ff, had the largest increases in
circulating 25(OH)D levels, as well as the largest decre-
ments in CRP and IL-6. Findings from other studies, such
as an inverse association between 1,25(OH)2D levels and
chronic kidney disease in patients with type 2 diabetes that
was significantly modified by FokI [31], support the notion
that vitamin D and/or polymorphisms in the VDR may be
important in diabetic physiopathology.
1.5.3 Rheumatoid Arthritis
A meta-analysis to determine the association between VDR
polymorphisms (BsmI, TaqI, FokI, and ApaI) and RA
susceptibility found that the FokI polymorphism was sig-
nificantly associated in Europeans [32]. More recent stud-
ies have found several VDR polymorphisms associated
with RA in different populations including South Asians
and Caucasians [33], Tunisians [34], and Egyptians [35].
These studies have had small sample sizes with 200 or
fewer cases each and replication is needed.
1.5.4 Myocardial Infarction
Few studies have investigated the role of VDR polymor-
phisms in MI susceptibility, although many observational
studies have shown an association between low 25(OH)D
levels and CVD. In patients aged \65 years, but not older
individuals, there is evidence that VDR BsmI significantly
associates with the presence of MI [36]. However, a new
polymorphism in the binding site of the primers used for
BsmI restriction polymorphism identification, causing
failure of polymerase chain reaction amplification with a
loss of the b allele in heterozygotes, may have confounded
this and other studies [37].
1.5.5 Cancer
Multiple studies have associated VDR polymorphisms with
cancer risk and progression, particularly for susceptibility
to lung [38] and ovarian cancers [39]. Results have gen-
erally been mixed and meta-analyses have suggested
positive results only for particular polymorphisms in cer-
tain populations. Significant associations have been
reported in breast cancer (FokI, BsmI, TaqI, ApaI, poly
(A)), prostate (FokI, BsmI, TaqI, poly (A)), skin (FokI,
BsmI, A-1210), colorectal (FokI, BsmI), ovary (FokI, ApaI),
and bladder (FokI) cancers, and in renal cell carcinoma
(TaqI, ApaI) [40].
Associations were strongest for breast (BsmI, FokI) and
prostate (FokI) cancers and malignant melanoma (FokI) on
systematic review [40]. However, an updated meta-analysis
for prostate cancer risk showed an association in Asian
populations for TaqI [41], but FokI and BsmI in diverse
populations showed no significant associations [42]. Lack
of association has also been reported in colorectal cancer
outcomes [43]. Meta-analysis of colorectal cancer risk
studies showed increased risk associated with BsmI poly-
morphisms, but not Cdx-2, FokI, ApaI, or TaqI, in Cau-
casians [44]. Breast cancer association studies have also
shown mixed results. A recent meta-analysis showed that
FokI is associated with breast cancer risk in diverse pop-
ulations while ApaI may be associated with Asian popu-
lations [45]. Other polymorphisms, such as VDR poly(A),
do not appear to be associated [46]. The VDR Cdx2
polymorphism was found to be significantly associated
with breast cancer susceptibility in Africans but not in
Caucasians [47].
1.5.6 Genome-Wide Association Studies and Vitamin D
Several vitamin D metabolism genes have been implicated
in GWAS of immunulogic, cancer, and inflammatory traits
(Table 2). However, increased susceptibility of hip
fracture, type 2 diabetes, RA, MI, and cancer other than
lung has not been observed in association with SNPs in
vitamin D metabolism genes. In particular, rs7968585,
associated with these major clinical outcomes by Levin
and colleagues [6], or variants in high linkage disequi-
librium (rs10783215, rs7965281, rs4760733; r2 [ 0.9),
have not been associated by GWAS. Differences in
populations studied and criteria for phenotypic charac-
terization among other issues may be responsible for
this lack of replication. Large-scale studies in homo-
geneous populations with carefully selected end-
points are needed before definitive conclusions can be
drawn.
1.6 Epidemiological Evidence Involving Mortality,
Vitamin D Levels, and Supplementation
A reverse J-shaped association between serum 25(OH)D
levels and all-cause mortality was confirmed in a large,
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prospective, population-based study [61]. Adjusted relative
risk (RR) with 95 % CI for all levels \60 nmol/L were
significantly above 1 when compared with the reference
group (75–99 nmol/L). Complementing this, a meta-ana-
lysis of vitamin D supplementation involving nearly 75,000
individuals from 32 trials concluded that vitamin D3
appears to decrease mortality from any cause (RR 0.94,
95 % CI 0.91–0.98), although mainly in elderly institu-
tionalized women [62].
1.6.1 Autoimmune Diseases
Many studies have investigated the relationship between
vitamin D levels, the risk of developing autoimmune




Name (function) Associated trait Strongest
SNP-risk
allele
P value OR 95 % CI References
VDR Vitamin D receptor Inflammatory
bowel disease
rs11168249-C 8.0E-09 1.05 [1.024–1.084] [48]
CYP27B1 25-hydroxyvitamin D3
1-alpha-hydroxylase




Atopic dermatitis rs16999165-T 2.0E-08 1.19 [1.12–1.26] [50]
Multiple sclerosis rs2248359-G 3.0E-11 1.12 [1.1–1.13] [51]
Lung cancer rs4809957 1.20E-08 1.13 [1.08–1.18] [52]
GC Vitamin D binding protein Non-alcoholic fatty
liver disease
histology (other)
rs222054-C 1.0E-06 2.54 [0.17–4.91] [53]
Metabolite levels rs1851024 1.0E-14 NR NR [54]
Vitamin D levels rs2282679 2.0E-14 NR NR [17]
Vitamin D insufficiency rs2282679 2.0E-109 NR NR [14]
Vitamin D levels rs2282679-C 2.0E-49 0.38 [0.32–0.44]
unit decrease
[17]
CUBN Cubilin*, renal and intestinal
endocytic receptor involved





rs1801239-T 1.0E-11 0.08 NR [55]
MRI atrophy measures rs6602175 3.0E-06 0.01 NR [56]
Folate pathway
vitamin levels





rs11254363-A 1.0E-06 21.49 [7.71–35.27]
pg/mL decrease
[58]
Quantitative traits rs10508517-A 6.0E-06 0.18 NR [59]
LRP2 Megalin**, also an endocytic





including uptake of GC
Anorexia nervosa rs830998 9.0E-06 NR NR [14]
Urate levels rs2544390-C 4.0E-08 0.08 [0.053–0.111]
unit decrease
[60]
CYP2R1 Vitamin D 25-hydroxylase Vitamin D insufficiency rs10741657 3.0E-20 NR NR [14]








availability for vitamin D
synthesis
Vitamin D insufficiency rs12785878 2.0E-27 NR NR [14]
Vitamin D levels rs3829251-A 3.0E-09 0.18 [0.12–0.24]
unit decrease
[17]
SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval, MRI magnetic resonance imaging, NR not reported
Data from http://www.genome.gov/gwastudies, accessed December, 27, 2013 except [52]
* Also known as intrinsic factor-cobalamin receptor
** Also known as low-density lipoprotein-related protein 2
Genetics of Vitamin D and Major Clinical Outcomes 265
diseases (AID), and if vitamin D supplements can modify
disease course. A recent meta-analysis identified 219 articles
with such outcomes and found that vitamin D deficiency
(\75 nmol/L) is highly prevalent in both healthy and diseased
individuals and that severe deficiency (\25 nmol/L) is asso-
ciated with increased symptomatology. However, among
interventional studies, it was found that only in type 1 diabetes
does vitamin D supplementation reduce the risk of suscepti-
bility with a dose-response effect [63].
1.6.2 Hip Fracture
Several trials have been carried out to assess the value of
vitamin D supplementation in the prevention of hip frac-
tures. A recent participant-level meta-analysis using 11
double-blind, randomized, controlled trials of oral vitamin
D supplementation, with or without calcium, compared
with placebo or calcium alone in those aged older than
65 years, concluded that supplementation with C800 IU
daily appeared of benefit in the prevention of hip and non-
vertebral fracture (HR, 0.70; 95 % CI 0.58–0.86, P value
\0.001; actual intake analysis for hip fracture) [64].
1.6.3 Type 2 Diabetes Mellitus
Many observational studies and a number of clinical trials
have been carried out to determine the relationship of
vitamin D blood levels and supplementation with type 2
diabetes and results remain inconclusive. Khan and col-
leagues recently reported a systematic review and meta-
analysis of prospective studies reporting association of
circulating or dietary vitamin D levels with incident type 2
diabetes, metabolic syndrome, and insulin resistance. They
found significant heterogeneity across studies and evidence
of publication bias but concluded that vitamin D status at
baseline in healthy adults is inversely associated with
increased susceptibility to type 2 diabetes (RR 0.81, 95 %
CI 0.71–0.92) and metabolic syndrome (RR 0.86, 95 % CI
0.80–0.92) [65].
A further systematic review and meta-analysis that
included 15 trials assessed the effect of vitamin D sup-
plementation on glycemic control and insulin resistance
[66]. It found no significant improvement in fasting glu-
cose, HbA(1c), or insulin resistance in those treated with
vitamin D compared with placebo. Larger trials in homo-
geneous populations are needed to determine whether
vitamin D supplementation is beneficial in glycemic con-
trol, insulin resistance, and type 2 diabetes prevention.
1.6.4 Rheumatoid Arthritis
Several studies have investigated the association between
vitamin D intake and RA susceptibility as well as 25(OH)D
levels and RA activity. A recent meta-analysis summarized
these studies and found an association between total vita-
min D intake and RA incidence without between-study
heterogeneity. Individuals had a 24.2 % lower risk of
developing RA when comparing highest vs. lowest vitamin
D intake groups. Vitamin D levels were also inversely
associated with RA activity [67].
Studies of vitamin D supplementation have not shown
benefit so far in RA. Vitamin D supplementation of 800 IU
per day appears ineffective in RA patients [68]. A large
study to determine whether calcium plus vitamin D sup-
plementation affects incidence of RA was carried out in the
Women’s Health Initiative. More than 36,000 women were
randomized to 1,000 mg calcium carbonate plus 400 IU of
vitamin D3 daily or to placebo. In intention-to-treat anal-
yses, no differences were observed in RA incidence
between treatment groups. Trials assessing higher doses are
required before conclusions can be reached [69].
1.6.5 Myocardial Infarction
Multiple studies have shown a high prevalence of vitamin
D deficiency in patients with CVD and an association of
vitamin D deficiency with higher mortality [70, 71]. Vita-
min D deficiency is also associated with an increased
incidence of cardiovascular risk factors including hyper-
tension, hyperlipidemia, MI, stroke, chronic kidney dis-
ease, and diabetes (reviewed in [72]). A recent prospective
evaluation in multi-ethnic populations free of known CVD
at baseline showed that white or Chinese, but not black or
Hispanic, individuals with low circulating 25(OH)D levels
were at significantly increased risk of MI, angina, cardiac
arrest, or death from CVD [73]. Severe vitamin D defi-
ciency in patients with acute coronary syndromes appears
to be significantly and independently associated with in-
hospital death [74].
Initial clinical trials to test whether supplementation
with vitamin D is beneficial in patients with CVD have
shown benefit [70]. Both low circulating 25(OH)D levels
and high plasma renin activity are associated independently
with poor prognosis in patients with chronic heart failure
[75, 76]. A recent open-label, blinded, endpoint, phase II
trial in cardiac heart failure patients showed that vitamin
D3 supplementation lowers plasma renin activity using
2,000 IU daily [77]. A large randomized trial in healthy
postmenopausal women from the Women’s Health Initia-
tive showed that calcium (500 mg) plus vitamin D (400 IU
daily) supplementation neither increased nor decreased
coronary risk [78].
Strong and independent associations of circulating
25(OH)D levels with cardiovascular mortality have been
shown but causality and benefit from supplementation
remain unresolved.
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1.6.6 Cancer
In vitro and animal models show strong evidence of anti-
proliferative and pro-apoptotic effects in cancer cells fol-
lowing calcitriol stimulation [79]. Many observational
studies have associated low circulating levels of 25(OH)D
with cancer susceptibility, particularly for colorectal cancer
[80]. A recent systematic review and meta-analysis of
longitudinal studies showed an inverse association of total
cancer incidence with circulating 25(OH)D levels [81].
Total cancer mortality was also assessed but studies
showed significant heterogeneity; however, other studies
have not shown an association. The Cohort Consortium
Vitamin D Pooling Project of Rarer Cancers did not show a
link between higher levels of vitamin D and reduced risk of
cancer [82]. Clinical trials have shown mixed results and
further studies are needed [83, 84].
1.7 Low Levels of 25-Hydroxyvitamin D
and Genotype in Major Clinical Disease Risk
The study by Levin et al. [6] showed an interaction
between rs7968585 (implicating VDR) and low 25-hy-
droxyvitamin D concentration with increasing risk of the
clinical composite outcome for individuals heterozygous
and homozygous for the risk allele. It would seem rea-
sonable to hypothesize that SNPs associated by GWAS
with circulating 25(OH)D levels could serve as proxies,
interact with VDR SNPs to determine disease risk, or be
independently associated by GWAS with disease. GWAS
have been carried out for these major disease outcomes and
have not shown an association for the most highly signif-
icant SNPs associated with vitamin D levels (Table 2).
Epistasis between SNPs found in or near vitamin D
metabolism genes has been shown [14]. Wang et al. [14]
combined the three confirmed variants and found that
individuals with a genotype score in the highest quartile
were at increased risk of having lower 25(OH)D circulating
levels (\75 nmol/L and \50 nmol/L) compared with the
lowest quartile. Integrating this information with disease
phenotypes, as suggested by the approach used by Levin
et al. [6], may reveal important insights and could help
identify individuals at greater risk of disease susceptibility.
The Tromsø Study, a prospective assessment of more
than 9,000 subjects in Norway, could not however support
or exclude a causal relationship between SNPs associated
with low 25(OH)D levels by GWAS and disease [85]. The
study followed more than 9,000 individuals for 13 years
with the endpoints MI, type 2 diabetes, cancer, death, or a
randomly selected control group with genotyping for 17
SNPs related to serum 25(OH)D levels (those initially
identified in [14, 17]). VDR variants were not included as
these had not been consistently shown to affect circulating
25(OH)D levels. Few other studies have assessed interac-
tions of this nature and more research is needed.
1.8 Future Studies Assessing Vitamin D–Gene
Interactions in Disease
1.8.1 Study Design and Analytical Considerations
Advances in the determination of genetic risk are greatly
improving our capacity to detect gene–environment inter-
actions (GEI). Although a detailed discussion of the study
of GEI is beyond the scope of this review, we will mention
several important aspects. Achieving sufficient power and
appropriate study design are particularly challenging. Four
designs have traditionally been used: family based, case-
control, cohort, and more recently, case-only [86, 87].
Obtaining sufficiently large samples sizes remains the
biggest obstacle in all. Susceptibility to population strati-
fication bias, recall bias, survivor bias, prospectively col-
lected samples for biomarker measurement, and sample
size are particularly relevant factors [88]. Analysis and
interpretation, especially for genome-wide designs, are
rapidly becoming bottlenecks as sample sizes and data sets
increase.
Case-only designs, where differences in the prevalence
of the exposure between genotype-positive vs. genotype-
negative cases would indicate an interaction, have recently
gained popularity as they require smaller sample sizes and
bias does not appear to be common in practice [86]. Case-
control studies in clinical settings for gene–drug interac-
tions have also been performed recently. The first large
randomized trials of the clinical utility of genotype-guided
dosing for vitamin K antagonists disappointingly showed
marginal or non-usefulness for initiation of anticoagulant
therapy [89–91]. Although results were not encouraging,
studies of this nature will likely be more common in the
future as we gain a better understanding of GEI and their
clinical relevance.
Mendelian randomization has served as a useful method
to interrogate GEI such as in hypertension risk and alcohol
intake [92] and incidence of coronary events and low-
density lipoprotein levels [93]. More recently, large studies
such as the National Cancer Institute Breast and Prostate
Cancer Cohort Consortium have provided examples of
candidate gene and genome-wide GEI analysis in prostate
cancer and steroid hormones including vitamin D [94, 95].
Contrary to experimental evidence, the study by Mondul
et al. [94] found that variants related to lower levels of
circulating 25(OH)D may actually be associated with a
decreased risk of aggressive prostate cancer.
The study by Levin et al. [6] has several strengths and
provides a useful starting point for discussion of study
design in genetic association and 25(OH)D analysis.
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Replication of findings in different and independently
recruited and ascertained populations greatly increases
confidence by reducing the likelihood of false-positive
results. Equally, independent analysis followed by meta-
analysis provides more robust methodology. Stringent
multiple testing correction is necessary. The use of a
composite outcome may increase statistical power,
although heterogeneity in phenotypic characterization
across cohorts and likely underlying biologic differences
in patho-physiology may counter this. Lifestyle factors,
comorbidity, time from 25(OH)D status measurement,
season of measurement, and body mass index need to be
considered when analyzing disease associations involving
circulating 25(OH)D levels.
Study outcomes and power must be clearly determined a
priori to further avoid the likelihood of false-positive and
false-negative results. Previous studies can aid in estimat-
ing effect size and sample sizes required. Initial recruit-
ment of a homogeneous population, particularly in terms of
genetic structure, is essential for successful genetic studies.
Bias in reporting, level of diagnostic ascertainment, and
known comorbidity are important factors that require
careful consideration and attention when characterizing
phenotypes for GWAS. The choice of platform to deter-
mine genotypes may need expert advice. For gene- or
pathway-focused studies, analysis of published data, hap-
lotype structure of the population of interest, and available
functional evidence in a disease-relevant context would
facilitate design and interpretation of results.
Finally, standardized methods of measurement of cir-
culating 25(OH)D levels across individuals and cohorts can
reduce artificial variation. Although 25(OH)D status is
stable across extended periods of time, repeated measure-
ments may be necessary. Despite intense debate, the report
by the Institute of Medicine (USA) in 2011 [13] established
thresholds for vitamin D levels that may aid comparisons
across cohorts and diseases.
1.8.2 Future Clinical Applications: SNP Profiling
for Identification and Treatment of At-Risk
Individuals?
The number of studies associating low levels of circulating
25(OH)D with disease risk have raised calls for public
health intervention. Should all individuals at particular
latitudes be supplemented with vitamin D through diet?
This question is far from trivial. Although proponents may
eventually be proved right, conclusive evidence for the
causal involvement and benefit from supplementation of
vitamin D in non-classical vitamin D-associated diseases is
still needed.
Interventions for individuals at greater risk could come
sooner and may be more appropriate given the current
evidence. Modification of lifestyle factors, while consid-
ering changes in risk for other diseases (i.e., increased sun
exposure in fair-skinned individuals), and seasonal and
dietary supplementation could be considered. Testing
before treating, particularly in light of increased mortality
at increased levels of circulating 25(OH)D [61], may be
suitable in certain patient groups.
Identification of individuals at increased disease risk by
genotype is a promising area. Evidence is currently insuf-
ficient to recommend this approach in vitamin D-related
diseases but the study by Levin et al. [6] further raises this
issue. Interestingly, Martineau et al. [96] showed in a
randomized, controlled clinical trial in patients being
treated for tuberculosis that vitamin D supplementation
significantly decreased time to mycobacterium sputum
clearance in individuals carrying rs731236 (TaqI [tt],
recently merged with rs7968585, the variant identified by
Levin et al. [6]).
2 Conclusions and Future Perspectives
Observational data clearly associate vitamin D with many
diseases and initial molecular evidence of the involvement
of vitamin D through the action of VDR exists for some of
these [97]. A causal role for vitamin D, other than in bone
disease, appears to be more likely in MS and type 1 dia-
betes. Strong evidence for other diseases is not yet
available.
Candidate gene association studies have many advan-
tages but have largely suffered from inconsistency and lack
replication. GWAS is a powerful approach to identify
disease-associated genetic variants and hundreds of phe-
notypes have now been catalogued. There has been a lack
of association of VDR polymorphisms in GWAS although
other genes important in vitamin D metabolism, such as
CYP24A1 and CYP27B1, have been strongly implicated.
Benefit from vitamin D supplementation is yet to be
systematically tested and future studies should address this
through careful study design with a particular focus on at-risk
individuals. Recent clinical trials of vitamin D supplemen-
tation have mostly used small numbers of individuals and
have been underpowered showing inconsistent results.
Vitamin D–gene interactions are likely to be important in
disease and require further study. VDR polymorphisms may
play an important role in determining disease risk and further
studies may need to take these variants, and those shown by
GWAS to be important in determining circulating 25(OH)D
levels, into careful consideration. Epistasis between variants
that determine vitamin D blood levels and VDR SNPs may
also be relevant and require investigation. Studies testing the
interaction between variants associated with vitamin D blood
levels, VDR polymorphisms, circulating 25(OH)D levels,
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and disease susceptibility may shed further insight into
patho-physiological mechanisms and could serve to identify
biomarkers. Genetic variant analysis as a means to identify
patients at risk is a promising approach. However, it is pre-
mature to recommend genotyping VDR in a clinical setting
and many more studies are needed before conclusive evi-
dence can be reached. It seems likely that both common and
rare variants in vitamin D metabolism genes play a role in
disease. Further research addressing this question could yield
additional insight that is clinically translatable.
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